Literature DB >> 31938855

PCSK9 is a promising prognostic marker in patients with advanced NSCLC.

Aldo Bonaventura1,2, Francesco Grossi3, Fabrizio Montecucco4,5.   

Abstract

Entities:  

Year:  2020        PMID： 31938855     DOI： 10.1007/s00262-020-02485-z

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


× No keyword cloud information.
  4 in total

1.  Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor.

Authors:  Khaldoun S Abdelwahed; Abu Bakar Siddique; Mohamed M Mohyeldin; Mohammed H Qusa; Amira A Goda; Sitanshu S Singh; Nehad M Ayoub; Judy Ann King; Seetharama D Jois; Khalid A El Sayed
Journal:  Pharmacol Res       Date:  2020-05-11       Impact factor: 7.658

Review 2.  Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition.

Authors:  Huimin Sun; Wen Meng; Jie Zhu; Lu Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-03-21       Impact factor: 3.000

3.  Bioinformatics Identification of Key Genes for the Development and Prognosis of Lung Adenocarcinoma.

Authors:  Xuan Luo; Jian Guo Xu; ZhiYuan Wang; XiaoFang Wang; QianYing Zhu; Juan Zhao; Li Bian
Journal:  Inquiry       Date:  2022 Jan-Dec       Impact factor: 2.099

4.  Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers.

Authors:  Emilie Wong Chong; France-Hélène Joncas; Nabil G Seidah; Frédéric Calon; Caroline Diorio; Anne Gangloff
Journal:  BMC Cancer       Date:  2022-10-06       Impact factor: 4.638
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.